Who Paid My Doc
Mohammad Ashraf
Reproductive Endocrinology Flint, MI Medical Doctor
NPI 1619087343 CMS profile 1064074
2 Hurley Plz, Suite 209, Flint, MI 48503
General payments
$263
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Mohammad Ashraf of Flint, MI is reported in the CMS Open Payments database as having received $263 across 3 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 25th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $263 | 3 |
Beside peers
- Mohammad Ashraf
- Reproductive Endocrinology median
- Middle half of Reproductive Endocrinology
- National median
In program year 2025, general payments to Mohammad Ashraf were reported at $0. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.
Show as a table
| Year | Mohammad Ashraf | Reproductive Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $196 | $77–$425 | $163 |
| 2020 | $0 | $81 | $35–$182 | $114 |
| 2021 | $0 | $102 | $43–$247 | $132 |
| 2022 | $0 | $139 | $62–$303 | $149 |
| 2023 | $0 | $141 | $65–$285 | $160 |
| 2024 | $263 | $144 | $65–$302 | $164 |
| 2025 | $0 | $141 | $66–$285 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
21
Drug cost
$308
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 21 | $308 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Reproductive Endocrinology in Michigan
Shahryar Kavoussi
Reproductive Endocrinology · Ann Arbor, MI
David Magyar
Reproductive Endocrinology · Dearborn, MI
Michael Diamond
Reproductive Endocrinology · Southfield, MI
Ali Bazzi
Reproductive Endocrinology · Livonia, MI
Laura Gago
Reproductive Endocrinology · Brighton, MI
Ahmad Hammoud
Reproductive Endocrinology · Bloomfield Hills, MI
Related records
Reproductive Endocrinology in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Reproductive Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.